Institutional Only|Drovix does not deal with individual investors and does not accept deposits or provide retail trading services.

Drovix.
Risk Warning

Risk Disclosure Policy

Drovix (MU) Ltd

Authorized and regulated by the Financial Services Commission (FSC) of Mauritius

Investment Dealer (Full Service Dealer) excluding Underwriting, License No. GB21026813

Registered Address: C/o SALVUS (Mauritius) Ltd, Silver Bank Tower, Ground Floor, 18 Bank Street, Cybercity, Ebene 72201, Mauritius

www.drovix.com

Effective Date: March 2026 | Model: Best Execution STP

1. Introduction

Drovix (MU) Ltd (hereinafter referred to as "the Company") is an alternative asset manager specialising in systematic investing. The Company is authorized and regulated by the Financial Services Commission (FSC) of Mauritius under Investment Dealer (Full Service Dealer) excluding Underwriting, License No. GB21026813.

INVESTMENT INVOLVES SIGNIFICANT RISK INCLUDING POSSIBLE LOSS OF ENTIRE AMOUNT. This Risk Disclosure is provided to institutional investors, professional investors, and qualified counterparties in connection with the Company's activities and offerings. Recipients should carefully consider whether an investment is appropriate in light of their objectives, experience, financial resources, and ability to bear loss.

IMPORTANT NOTICE: Exclusively for institutional investors, professional investors, and qualified counterparties. Not intended for retail investors.

2. General Investment Risks

Alternative investment strategies, including systematic and quantitative approaches, may involve greater risks than traditional long-only investments. Returns can be volatile, and there is no assurance that investment objectives will be achieved.

3. Strategy-Specific Risks

3.1 Systematic Macro: Trend-following and multi-asset systematic strategies are exposed to prolonged adverse trends, sharp reversals, and periods of poor performance. Model risk arises where signals, parameters, or assumptions do not perform as expected. Correlation and diversification assumptions may break down, particularly during stress periods.

3.2 Statistical Arbitrage: Market neutrality may not be maintained at all times; residual factor, basis, and financing exposures can produce losses. Convergence trades may fail to converge or may diverge further. Crowding among similar strategies can amplify drawdowns. Short selling involves the risk of unlimited loss on short positions and additional borrow, recall, and financing risks.

4. Market and Economic Risks

Investments are subject to market risk, including volatility and sudden price movements. Liquidity risk may limit the ability to exit positions at desired prices or times. Interest rate, currency, and credit or counterparty risks may adversely affect valuations and cash flows. Geopolitical events, policy changes, and regulatory developments can materially impact markets and strategies.

5. Operational Risks

Operational risks include technology failures, cyber incidents, and service provider disruptions. Model and algorithm risk arises from design errors, coding issues, or flawed assumptions. Data quality, availability, and interpretation errors may affect outputs. Key person and staffing risk may affect research, implementation, or oversight. Business continuity events may interrupt normal operations.

6. Leverage and Derivatives

Use of leverage and derivatives can amplify both gains and losses. Counterparty default or restructuring may affect exposures. Margin, collateral, and liquidity requirements may force reductions or liquidations at unfavourable times. Certain instruments may be illiquid or difficult to value.

7. Concentration and Diversification Risks

Concentration in markets, factors, instruments, or counterparties can increase the impact of adverse events. Conversely, diversification does not assure a profit or eliminate risk of loss.

  • Concentrated exposure to a single strategy, sector, region, or risk factor may result in magnified losses;
  • Limited diversification across managers, signals, or time horizons may increase correlation during stress;
  • Investors should assess portfolio construction and concentration in light of their risk tolerance and objectives.

These concentration and diversification considerations are illustrative and not exhaustive.

8. Valuation Risks

8.1 OTC and illiquid instruments

Over-the-counter derivatives, private instruments, and thinly traded positions may rely on subjective judgment, model-based valuations, or counterparty marks. Reported values may differ materially from amounts realised on exit.

9. Tax and Legal Risks

9.1 Investor responsibility

Each investor is responsible for its own tax, legal, and regulatory position. Laws and regulations change; tax treatment of income, gains, and withholding may vary by jurisdiction. The Company does not provide tax or legal advice.

10. No Guarantee of Returns; Risk Management

Past performance is not indicative of future results. There is no guarantee that targeted returns or risk parameters will be achieved.

The Company may employ risk management frameworks, controls, and monitoring; however, such measures cannot eliminate all risks or prevent losses, including loss of the entire investment.

11. Investor Acknowledgement

By proceeding with an investment or relationship with the Company, the investor confirms that it has read, understood, and accepted the risks described in this disclosure (and related documentation), and that it is willing and able to bear the potential loss of its entire investment.

Drovix (MU) Ltd | Financial Services Commission (FSC) of Mauritius | License No. GB21026813